Last updated: September 23, 2026
Sonidegib phosphate, marketed as Odomzo by Novartis, is a hedgehog pathway inhibitor approved for adults with locally advanced basal cell carcinoma (BCC) that has recurred after surgery or radiation, or patients who are not candidates for those treatments. Its commercial position is constrained by a narrow indication, class toxicity, competition from vismodegib, and the availability of surgery and radiation for most BCC patients. Novartis does not disclose Odomzo revenue as a standalone line item, preventing a reliable public calculation of annual sales, margins, or product-level growth.
What is the current FDA status of sonidegib phosphate?
The U.S. Food and Drug Administration approved Odomzo on July 24, 2015, under the accelerated approval pathway. The approval was based on objective response data in patients with locally advanced or metastatic BCC enrolled in the BOLT study. The approved indication covers locally advanced BCC that has recurred after surgery or radiation, or patients who are not candidates for those treatments. Odomzo is not approved for routine treatment of metastatic BCC as a broad first-line therapy outside the labeled population. [1]
| Attribute |
Sonidegib phosphate |
| Brand |
Odomzo |
| Active ingredient |
Sonidegib phosphate |
| Company |
Novartis |
| Drug class |
Smoothened, or SMO, inhibitor |
| Initial U.S. approval |
July 24, 2015 |
| U.S. dosage form |
200 mg oral capsule |
| Primary indication |
Locally advanced BCC |
| FDA pathway |
Accelerated approval |
| Principal competitor |
Vismodegib, marketed as Erivedge |
| Biosimilar exposure |
None |
| Generic exposure |
Potentially material after applicable small-molecule exclusivity and patent barriers expire |
The FDA label warns of muscle spasms, alopecia, dysgeusia, weight loss, nausea, fatigue, and musculoskeletal pain. Sonidegib also carries embryo-fetal toxicity warnings and a risk of rhabdomyolysis. These adverse events restrict treatment persistence and can reduce the drug's economic value relative to local therapy or competing systemic treatment. [1]
How does sonidegib compare with vismodegib?
Sonidegib competes directly with vismodegib, another oral hedgehog pathway inhibitor. Vismodegib was approved earlier and has stronger commercial recognition in advanced BCC. Sonidegib's principal differentiation is its clinical positioning in locally advanced disease and its use at a 200 mg daily dose, rather than a clearly superior safety profile.
| Category |
Sonidegib |
Vismodegib |
| Brand |
Odomzo |
Erivedge |
| Company |
Novartis |
Roche/Genentech |
| Target |
SMO |
SMO |
| U.S. approval |
2015 |
2012 |
| Main BCC use |
Locally advanced BCC |
Locally advanced or metastatic BCC |
| Administration |
Oral capsule |
Oral capsule |
| Major commercial issue |
Narrow market and toxicity |
Mature brand, toxicity, and generic pressure |
| Biosimilar risk |
None |
None |
| Competitive advantage |
Alternative hedgehog inhibitor |
Earlier entry and broader labeled disease scope |
Clinical selection is often driven by tolerability, prior treatment, physician experience, payer policy, and patient preference rather than a decisive efficacy advantage. Both products face limitations from class-related toxicity. Treatment interruption and discontinuation are relevant because advanced BCC often affects older patients who may have substantial comorbidity.
What is the market size for sonidegib phosphate?
The addressable market is substantially smaller than the overall BCC population. BCC is the most common skin cancer, but most cases are cured by excision, Mohs surgery, radiation, or other local treatment. Only a small subset develops locally advanced or metastatic disease that is unsuitable for surgery or radiation.
The commercial funnel is therefore narrow:
- A large diagnosed BCC population.
- A smaller group with advanced or recurrent disease.
- A smaller group unsuitable for local treatment.
- A still smaller group eligible for systemic hedgehog inhibition.
- A subset able to remain on treatment despite adverse events.
This structure limits unit volume. Pricing can be high because Odomzo is an oncology specialty product, but high price does not offset the restricted patient pool, competition from vismodegib, treatment discontinuation, and the later arrival of immune checkpoint inhibition.
Cemiplimab, marketed as Libtayo, is approved for patients with locally advanced or metastatic BCC who have progressed on a hedgehog pathway inhibitor or are intolerant to one. This creates a treatment sequence in which sonidegib may be used before immunotherapy, but it also gives prescribers another systemic option after hedgehog pathway failure. [2]
What is the financial trajectory of Odomzo?
Novartis does not separately report Odomzo revenue in its public annual reports. Odomzo is grouped within broader pharmaceutical or oncology reporting, if reported at all, rather than disclosed as a product-level revenue line. A precise year-by-year financial trajectory cannot therefore be established from public filings.
| Financial metric |
Public status |
| Annual Odomzo revenue |
Not separately disclosed by Novartis |
| Product gross margin |
Not disclosed |
| Product operating profit |
Not disclosed |
| Regional revenue |
Not disclosed at product level |
| Prescription volume |
Not disclosed in company filings |
| Development spending |
Not separately disclosed |
| Acquisition or licensing payment |
No major publicly disclosed transaction identified as a current driver of Odomzo economics |
The available commercial indicators point to a mature, niche product rather than a growth asset. Odomzo entered a market with an incumbent hedgehog inhibitor and did not become a major Novartis revenue contributor. Its revenue trajectory is likely shaped by the following factors:
- Low eligible patient volume.
- Physician familiarity with Erivedge.
- High discontinuation rates associated with class toxicity.
- Use of surgery and radiation before systemic therapy.
- Competition from cemiplimab after hedgehog pathway treatment.
- Potential generic entry following loss of relevant exclusivity.
- Limited opportunity for large-label expansion.
The absence of standalone revenue disclosure means that investor analysis should treat Odomzo as a non-material contributor to consolidated Novartis sales unless a transaction, divestiture, or product-specific disclosure changes that assessment.
When does sonidegib lose exclusivity?
Sonidegib is a small-molecule drug, so biosimilar regulations do not apply. Generic competition would proceed through an abbreviated new drug application, commonly involving Paragraph IV patent certifications against listed patents.
The commercial timing depends on three separate protections:
| Protection |
Relevance to Odomzo |
| Regulatory exclusivity |
The original accelerated approval provided a limited period of orphan-drug exclusivity tied to the approved indication |
| Orange Book patents |
Listed patents may delay or trigger litigation against an ANDA applicant |
| Formulation and use patents |
These may protect particular compositions, dosing approaches, or treatment methods but may not block every generic pathway |
Odomzo received orphan-drug designation for advanced BCC, which generally provides seven years of U.S. market exclusivity from approval for the same indication. The seven-year period associated with the 2015 approval would have ended in 2022, subject to the precise scope of the designation and any regulatory complications. Regulatory exclusivity alone therefore is no longer the principal barrier to U.S. generic entry. [3]
The relevant patent expiration date cannot be reduced to a single reliable public date without an up-to-date review of the FDA Orange Book, patent-term-adjustment records, terminal disclaimers, and any litigation-specific extensions. Patent expiry may differ by jurisdiction and by claim category. Commercial generic entry could occur before or after a nominal patent expiry depending on Paragraph IV litigation, settlement terms, pediatric extensions, or the generic applicant's decision to market with a skinny label.
What patents protect sonidegib phosphate?
The patent estate is expected to include multiple claim categories:
Compound patents
Compound claims cover sonidegib and related hedgehog pathway antagonists. These claims usually provide the earliest and broadest protection but are also the patents most likely to face invalidity, non-infringement, or expiration challenges as the product matures.
Pharmaceutical composition patents
Composition patents may cover sonidegib phosphate, specific solid forms, capsule formulations, excipient combinations, particle characteristics, or stability features. These patents can complicate generic substitution even after the core compound patent expires.
Method-of-use patents
Method claims may cover treatment of advanced BCC, dosing regimens, patient selection, or use after failure of local treatment. A generic applicant may attempt a Paragraph VIII statement or a skinny-label strategy if protected use claims can be omitted from the proposed labeling.
Manufacturing patents
Manufacturing and crystallization patents can increase the cost of generic development and create process risk. They generally do not prevent a generic company from using a non-infringing process if the final product meets the required quality standards.
The practical strength of the estate depends on claim breadth, remaining patent term, Orange Book listing status, prior-art exposure, and whether the patents cover the active ingredient or only narrower formulations and uses. A mature oral oncology product with a narrow indication often has greater exposure to design-around strategies than a complex biologic or device combination.
What is the Orange Book status of Odomzo?
Odomzo's Orange Book position is commercially important because listed patents can trigger statutory stays after a Paragraph IV notice. The FDA Orange Book identifies approved products, patent information, and applicable exclusivity data. [4]
A generic applicant seeking approval may:
- Certify that no relevant patent is listed.
- Certify that a listed patent has expired.
- File a Paragraph III certification agreeing to wait until patent expiry.
- File a Paragraph IV certification alleging that a patent is invalid, unenforceable, or not infringed.
- Use a Paragraph VIII statement to omit a protected method of use.
A Paragraph IV filing would create litigation risk for the patent holder and could delay approval for up to 30 months if the brand company files suit within the statutory period. The absence of a widely reported high-profile Odomzo Paragraph IV case suggests that generic challenges have not produced the same public litigation profile as larger oncology brands, but that does not eliminate future entry risk.
Which companies are challenging sonidegib?
No major publicly reported U.S. Paragraph IV challenge has established a visible litigation market around Odomzo comparable to heavily litigated blockbuster drugs. Potential challengers would most likely include large generic companies with oncology manufacturing capabilities, such as Teva, Viatris, Sandoz, Sun Pharma, Dr. Reddy's Laboratories, or Zydus, although a company-specific challenge should not be assumed without an FDA filing or court docket.
Competition is more immediate from alternative therapies than from direct generic substitution. Relevant competitors include:
- Vismodegib from Roche/Genentech.
- Cemiplimab from Regeneron and Sanofi.
- Local surgery and Mohs surgery.
- Radiation therapy.
- Clinical trials involving immunotherapy or other targeted agents.
What generic launch risks exist for Odomzo?
The most likely launch scenarios are:
| Scenario |
Commercial effect |
| No early generic challenge |
Novartis retains niche revenue until patent barriers expire |
| Paragraph IV challenge with settlement |
Entry may occur on a negotiated date before final patent expiry |
| Skinny-label generic |
Generic competes for non-protected uses while avoiding listed method claims |
| Full-label generic after patent expiry |
Rapid price erosion and loss of branded volume |
| Limited generic uptake |
Small eligible population and oncology prescribing complexity slow substitution |
| Formulation patent survives |
Generic may launch with an alternative formulation or delayed entry |
Because Odomzo is an oral capsule rather than an injectable biologic, generic substitution could be operationally straightforward once blocking patents lapse. The economic impact would likely be a steep decline in net price and branded volume, although the absolute revenue loss to Novartis would probably be modest relative to major oncology franchises.
How strong is the sonidegib patent estate?
The estate is commercially moderate rather than exceptionally strong. The active ingredient and formulation may support meaningful protection, but the product lacks the characteristics that typically sustain long-term exclusivity: a large chronic-use population, multiple high-value indications, a complex biologic manufacturing process, or a device-linked delivery system.
The strongest barriers are likely to be valid, unexpired compound or composition claims. Method-of-use patents provide narrower protection because generic applicants may omit protected indications. Manufacturing patents can raise development costs but usually do not create an absolute market barrier.
What licensing deals affect sonidegib phosphate?
Sonidegib was developed and commercialized by Novartis under the Odomzo brand. No major current licensing transaction is publicly identified as a primary determinant of Odomzo revenue, market access, or patent ownership. The economic analysis is therefore centered on Novartis commercialization, competing hedgehog inhibitors, downstream immunotherapy, and generic entry rather than royalty-sharing arrangements.
Key Takeaways
- Sonidegib phosphate is a niche oral oncology product for locally advanced BCC.
- Novartis does not separately disclose Odomzo sales, preventing a precise product-level financial forecast.
- The product faces direct competition from vismodegib and sequential competition from cemiplimab.
- Its original orphan-drug exclusivity period has ended.
- Generic risk depends on the remaining Orange Book patent estate, Paragraph IV activity, and formulation or method-of-use protection.
- Small eligible patient numbers limit revenue upside.
- Class toxicity reduces treatment persistence and weakens the commercial position of both hedgehog inhibitors.
- The likely post-exclusivity outcome is material price erosion but limited impact on total Novartis revenue.
FAQs About Sonidegib Phosphate Market and Exclusivity
Is sonidegib phosphate a biologic drug?
No. Sonidegib phosphate is a synthetic small-molecule oral drug. Biosimilar approval rules do not apply; future competitors would generally pursue abbreviated new drug applications.
Is Odomzo still commercially available in the United States?
Odomzo remains an FDA-approved product. Commercial availability can vary by specialty pharmacy, payer coverage, and regional distribution.
Does sonidegib have a broader market than vismodegib?
No. Sonidegib has a narrower commercial position because its U.S. label is centered on locally advanced BCC, while vismodegib has a broader labeled position that includes metastatic BCC.
Can a generic version of Odomzo omit the basal cell carcinoma indication?
Potentially. A generic applicant may use a Paragraph VIII statement or a skinny-label strategy to omit protected methods of use, subject to FDA requirements and patent litigation risk.
What is the main long-term threat to Odomzo revenue?
The main threats are generic substitution after relevant patent barriers lapse, limited patient volume, treatment-limiting toxicity, and the use of immune checkpoint inhibitors after hedgehog pathway inhibitor therapy.
References
-
U.S. Food and Drug Administration. (2015). Odomzo (sonidegib) prescribing information.
-
U.S. Food and Drug Administration. (2018). Libtayo (cemiplimab-rwlc) prescribing information.
-
U.S. Food and Drug Administration. (2024). Orphan drug product designation database.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
-
Novartis AG. (2024). Annual report 2023.
